HER‐2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study

Since the initial reports of human epidermal growth factor receptor 2 (HER‐2) expression as being prognostic in osteosarcoma, numerous small studies varying in the interpretation of the immunohistochemical (IHC) staining patterns have produced conflicting results. The Children's Oncology Group therefore embarked on a prospective biology study in a larger sample of patients to define in osteosarcoma the prognostic value of HER‐2 expression using the methodology employed in the initial North American study describing an association between HER‐2 expression and outcome.

[1]  S. Lipshultz,et al.  Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Wen,et al.  The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. , 2012, Oncology letters.

[3]  R. Gorlick,et al.  Osteosarcoma: a review of diagnosis, management, and treatment strategies. , 2010, Clinical advances in hematology & oncology : H&O.

[4]  R. Gorlick,et al.  HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies , 2010, Expert opinion on pharmacotherapy.

[5]  S. Bakhshi,et al.  Her-2/neu, P-53, and Their Coexpression in Osteosarcoma , 2009, Journal of pediatric hematology/oncology.

[6]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[7]  A. Varan,et al.  C‐erbB‐2 expression and prognostic significance in osteosarcoma , 2008, Pediatric blood & cancer.

[8]  Zhengjia Chen,et al.  Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Squire,et al.  HER2 Amplification and Overexpression Is Not Present in Pediatric Osteosarcoma: A Tissue Microarray Study , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[10]  P. Ellis,et al.  Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.

[11]  P. Picci,et al.  Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. , 2005, European journal of cancer.

[12]  J. Montie.  Her-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. , 2005, The Journal of urology.

[13]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[14]  F. Bertoni,et al.  Quantitative assessment of HER2/neu expression by real-time PCR and fluorescent in situ hybridization analysis in low-grade osteosarcoma. , 2004, Oncology Report.

[15]  S. Ferrari,et al.  Evaluation of P‐glycoprotein, HER‐2/ErbB‐2, p53, and Bcl‐2 in primary tumor and metachronous lung metastases in patients with high‐grade osteosarcoma , 2004, Cancer.

[16]  M. J. van de Vijver,et al.  Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. , 2004, European journal of cancer.

[17]  T. Giordano,et al.  Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.

[18]  M. Hameed,et al.  HER-2/neu and p53 in Osteosarcoma: An Immunohistochemical and Fluorescence In Situ Hybridization Analysis , 2004, Cancer investigation.

[19]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[20]  R. Goldsby,et al.  HER-2/ neu Expression in Osteosarcoma Increases Risk of Lung Metastasis and Can Be Associated With Gene Amplification , 2003, Journal of pediatric hematology/oncology.

[21]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical , 2002 .

[22]  Toshihiko Yamashita,et al.  ErbB2 expression is correlated with increased survival of patients with osteosarcoma , 2002, Cancer.

[23]  T. Giordano,et al.  Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Tonya S. King,et al.  Clinicopathologic Analysis of HER-2/neu Immunoexpression among Various Histologic Subtypes and Grades of Osteosarcoma , 2001, Modern Pathology.

[25]  A. Maitra,et al.  Amplification of the HER‐2/neu oncogene is uncommon in pediatric osteosarcomas , 2001, Cancer.

[26]  N. Sawada,et al.  Loss of ErbB2 Expression in Pulmonary Metastatic Lesions in Osteosarcoma , 2001, Oncology.

[27]  J. Manola,et al.  Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[28]  R. Dillman,et al.  Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.

[29]  A. Huvos,et al.  Expression of HER2/erbB-2 correlates with survival in osteosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  F. Sarkar,et al.  HER‐2/neu Expression in Pancreatic Adenocarcinoma: Relation to Tumor Differentiation and Survival , 1997, Pancreas.

[31]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[32]  V. Barnett,et al.  Applied Linear Statistical Models , 1975 .

[33]  R. Gorlick,et al.  New targets and approaches in osteosarcoma. , 2013, Pharmacology & therapeutics.

[34]  D. Slamon,et al.  Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy , 2004, Breast Cancer Research and Treatment.

[35]  D. Parsch,et al.  Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue , 2004, Laboratory Investigation.

[36]  P. Bunn,et al.  HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. , 2000, Seminars in oncology.

[37]  H. Horiuchi,et al.  ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma , 1996, Cancer.

[38]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[39]  Stephen E. Fienberg,et al.  Discrete Multivariate Analysis: Theory and Practice , 1976 .